Cataflam

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Diclofenac potassium 25mg;  ;  

Saadav alates:

Novartis Consumer Health Australasia Pty Ltd (NZ)

INN (Rahvusvaheline Nimetus):

Diclofenac potassium 25 mg

Annus:

25 mg

Ravimvorm:

Tablet

Koostis:

Active: Diclofenac potassium 25mg     Excipient: Calcium phosphate Colloidal silicon dioxide Iron oxide red Macrogol 8000 Magnesium stearate Maize starch Microcrystalline cellulose Opacode brown S-1-9210HV Povidone   Purified talc Sodium starch glycolate Sucrose Titanium dioxide

Ühikuid pakis:

Blister pack, 10 tablets

Klass:

Restricted

Retsepti tüüp:

Restricted

Valmistatud:

Novartis Pharma AG

Toote kokkuvõte:

Package - Contents - Shelf Life: Blister pack, - 10 tablets - 30 months from date of manufacture stored at or below 30°C - Blister pack, - 20 tablets - 30 months from date of manufacture stored at or below 30°C - Blister pack, - 30 tablets - 30 months from date of manufacture stored at or below 30°C

Loa andmise kuupäev:

1988-10-20

Toote omadused

 
NEW ZEALAND DATASHEET 

NAME OF MEDICINE 
CATAFLAM
®
 Tablets 
Diclofenac potassium tablets 25 mg 
PRESENTATION 
Each  Cataflam  tablet  contains  25  mg  of  diclofenac  potassium.  The  tablets  are  pale  red,  round, 
biconvex sugar-
coated with
“CG” on one side and “DD” on the other. The diameter is about 7.7 mm 
with a thickness of about 5.0 mm.  
USES 
ACTIONS 

PHARMACOTHERAPEUTIC GROUP 
Non-steroidal anti-inflammatory drug (NSAID). 

MECHANISM OF ACTION 
Cataflam  tablets  contain  the  potassium  salt  of  diclofenac,  a  non-steroidal  compound  with 
pronounced analgesic, anti-inflammatory, and antipyretic
properties.  

Cataflam  tablets  have  a  rapid  onset  of  action  which  makes  them  particularly  suitable  for  the 
treatment  of  acute  painful  and  inflammatory  conditions.  Inhibition  of  prostaglandin  biosynthesis, 
which has been demonstrated in experiments, is considered to
be fundamental to its mechanism of 
action. Prostaglandins play a major role
in causing inflammation, pain, and fever. 

Diclofenac  potassium  _in  vitro_  does  not  suppress  proteoglycan  biosynthesis  in  cartilage  at 
concentrations equivalent to the concentrations reached in
humans. 

PHARMACODYNAMIC EFFECTS 
Cataflam has been found to exert a pronounced analgesic effect in moderate and severe pain. In 
the  presence  of  inflammation,  e.g.  due  to  trauma  or  following  surgical  interventions,  it  rapidly 
relieves both spontaneous pain and pain on movement and diminishes inflammatory swelling and 
wound  oedema.  Clinical  studies  have  also  revealed  that  in  primary  dysmenorrhoea  the  active 
substance is capable of relieving the pain and reducing the extent of bleeding.